v3.26.1
CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Parent Company
Angi Inc.
Total People Incorporated Shareholders' Equity
Total People Incorporated Shareholders' Equity
Parent Company
Total People Incorporated Shareholders' Equity
Angi Inc.
Common Stock
Common Stock
Common Stock
Class B common stock
Additional Paid-in-Capital
Additional Paid-in-Capital
Angi Inc.
Accumulated Deficit
Accumulated Other Comprehensive (Loss) Income
Accumulated Other Comprehensive (Loss) Income
Angi Inc.
Treasury Stock
Treasury Stock
Parent Company
Noncontrolling Interests
Noncontrolling Interests
Angi Inc.
Balance at beginning of period at Dec. 31, 2024 $ 25,415                                
Increase (Decrease) in Redeemable Noncontrolling Interests                                  
Net earnings 88                                
Adjustment of noncontrolling interests to redemption amount (191)                                
Other (33)                                
Balance at end of period at Jun. 30, 2025 25,279                                
Balance at beginning of period at Dec. 31, 2024 6,278,973     $ 5,577,898     $ 8 $ 1 $ 6,380,700   $ (538,974) $ (11,396)   $ (252,441)   $ 701,075  
Balance at beginning of period (in shares) at Dec. 31, 2024             84,831 5,789                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Net earnings (loss) (4,023)     (5,353)             (5,353)         1,330  
Other comprehensive income (loss), net of income taxes 1,105     672               672       433  
Stock-based compensation expense (1,577)     (3,369)         (3,369)             1,792  
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (in shares)             1,115                    
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (45,179)   $ (4,572) (45,179)   $ (8,260)     (45,179) $ (8,264)     $ 4       $ 3,688
Forfeiture of the Company's former CEO's restricted common stock award (in shares)             (3,000)                    
Withholding taxes paid on transfer of Angi Inc. Class B shares to the Company's former CEO (9,347)     (9,347)         (9,347)                
Purchase of treasury stock   $ (201,525) $ (10,688)   $ (201,525) $ (10,688)       $ (10,688)         $ (201,525)    
Adjustment of noncontrolling interests to redemption amount 191     191         191                
Adjustment to the liquidation value of Vivian Health preferred shares 0     (1,020)         (1,020)             1,020  
Distribution of the Company's investment in Angi Inc. (1,065,994)     (1,065,994)         (1,065,612)     (382)          
Elimination of Angi Inc. noncontrolling interest 0     682,927         682,927             (682,927)  
Other 139     139         139                
Balance at end of period (in shares) at Jun. 30, 2025             82,946 5,789                  
Balance at end of period at Jun. 30, 2025 4,937,503     4,911,092     $ 8 $ 1 5,920,478   (544,327) (11,102)   (453,966)   26,411  
Balance at beginning of period at Mar. 31, 2025 25,294                                
Increase (Decrease) in Redeemable Noncontrolling Interests                                  
Net earnings 96                                
Adjustment of noncontrolling interests to redemption amount (78)                                
Other (33)                                
Balance at end of period at Jun. 30, 2025 25,279                                
Balance at beginning of period at Mar. 31, 2025 4,737,438     4,713,559     $ 8 $ 1 5,913,590   (755,779) (10,993)   (433,268)   23,879  
Balance at beginning of period (in shares) at Mar. 31, 2025             82,622 5,789                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Net earnings (loss) 210,537     211,452             211,452         (915)  
Other comprehensive income (loss), net of income taxes (109)     (109)               (109)          
Stock-based compensation expense 19,475     17,031         17,031             2,444  
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (in shares)             324                    
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (9,320)     (9,320)         (9,320)                
Purchase of treasury stock (20,698)     (20,698)                   (20,698)      
Adjustment of noncontrolling interests to redemption amount 78     78         78                
Adjustment to the liquidation value of Vivian Health preferred shares 0     (1,003)         (1,003)             1,003  
Other 102     102         102                
Balance at end of period (in shares) at Jun. 30, 2025             82,946 5,789                  
Balance at end of period at Jun. 30, 2025 4,937,503     4,911,092     $ 8 $ 1 5,920,478   (544,327) (11,102)   (453,966)   26,411  
Balance at beginning of period at Dec. 31, 2025 25,264                                
Balance at end of period at Mar. 31, 2026 12,236                                
Balance at beginning of period at Dec. 31, 2025 4,763,759     4,733,827     $ 8 $ 1 5,959,692   (643,000) (11,842)   (571,032)   29,932  
Balance at beginning of period (in shares) at Dec. 31, 2025             83,581 5,789                  
Balance at end of period (in shares) at Mar. 31, 2026             84,083 5,789                  
Balance at end of period at Mar. 31, 2026 4,582,449     4,549,452     $ 8 $ 1 5,974,269   (714,882) (14,054)   (695,890)   32,997  
Balance at beginning of period at Dec. 31, 2025 25,264                                
Increase (Decrease) in Redeemable Noncontrolling Interests                                  
Net earnings 278                                
Adjustment of noncontrolling interests to redemption amount (13,277)                                
Other (29)                                
Balance at end of period at Jun. 30, 2026 12,236                                
Balance at beginning of period at Dec. 31, 2025 4,763,759     4,733,827     $ 8 $ 1 5,959,692   (643,000) (11,842)   (571,032)   29,932  
Balance at beginning of period (in shares) at Dec. 31, 2025             83,581 5,789                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Net earnings (loss) 436,891     434,969             434,969         1,922  
Other comprehensive income (loss), net of income taxes (1,921)     (1,921)               (1,921)          
Stock-based compensation expense 52,346     51,875         51,875             471  
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (in shares)             601                    
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (19,312)     (19,312)         (19,312)                
Purchase of treasury stock (133,245)     (133,245)                   (133,245)      
Payment received pursuant to the tax sharing agreement with Angi Inc. post distribution 8,491     8,491         8,491                
Allocation of certain tax attributes in connection with the Angi Inc. Distribution (1,104)     (1,104)         (1,104)                
Adjustment to the Angi Inc. Distribution following the repeal of Canada's digital service tax (1,460)     (1,460)         (1,460)                
Adjustment of noncontrolling interests to redemption amount 13,277     13,277         13,277                
Adjustment to the liquidation value of Vivian Health preferred shares 0     (3,182)         (3,182)             3,182  
Other 166     166         166                
Balance at end of period (in shares) at Jun. 30, 2026             84,182 5,789                  
Balance at end of period at Jun. 30, 2026 5,117,888     5,082,381     $ 8 $ 1 6,008,443   (208,031) (13,763)   (704,277)   35,507  
Balance at beginning of period at Mar. 31, 2026 12,236                                
Increase (Decrease) in Redeemable Noncontrolling Interests                                  
Net earnings 213                                
Adjustment of noncontrolling interests to redemption amount (186)                                
Other (27)                                
Balance at end of period at Jun. 30, 2026 12,236                                
Balance at beginning of period at Mar. 31, 2026 4,582,449     4,549,452     $ 8 $ 1 5,974,269   (714,882) (14,054)   (695,890)   32,997  
Balance at beginning of period (in shares) at Mar. 31, 2026             84,083 5,789                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Net earnings (loss) 507,626     506,851             506,851         775  
Other comprehensive income (loss), net of income taxes 291     291               291          
Stock-based compensation expense 34,997     34,879         34,879             118  
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (in shares)             99                    
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (1,271)     (1,271)         (1,271)                
Purchase of treasury stock (8,387)     (8,387)                   (8,387)      
Payment received pursuant to the tax sharing agreement with Angi Inc. post distribution 1,949     1,949         1,949                
Adjustment of noncontrolling interests to redemption amount 186     186         186                
Adjustment to the liquidation value of Vivian Health preferred shares 0     (1,617)         (1,617)             1,617  
Other 48     48         48                
Balance at end of period (in shares) at Jun. 30, 2026             84,182 5,789                  
Balance at end of period at Jun. 30, 2026 $ 5,117,888     $ 5,082,381     $ 8 $ 1 $ 6,008,443   $ (208,031) $ (13,763)   $ (704,277)   $ 35,507